Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Rating) have earned an average rating of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 […]
StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) in a research note released on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Other equities research analysts have also issued research reports about the stock. EF Hutton Acquisition Co. I reaffirmed a buy rating and issued a […]
StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) in a research report released on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock. A number of other equities analysts also recently issued reports on ADAP. EF Hutton Acquisition Co. I reiterated a buy rating and set a $10.00 […]